Published March 27, 2013
| Version v1
Journal article
Open
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk
Creators
- Couch, Fergus J.1
- Wang, Xianshu1
- McGuffog, Lesley2
- Lee, Andrew2
- Olswold, Curtis1
- Kuchenbaecker, Karoline B.2
- Soucy, Penny3
- Fredericksen, Zachary1
- Barrowdale, Daniel2
- Dennis, Joe2
- Gaudet, Mia M.4
- Dicks, Ed2
- Kosel, Matthew1
- Healey, Sue5
- Sinilnikova, Olga M.6
- Lee, Adam1
- Bacot, François7
- Olopade, Olufunmilayo I.8
- Rodriguez, Gustavo C.8
- Huo, Dezheng8
- 1. Mayo Clinic
- 2. University of Cambridge
- 3. Universitaire de Québec
- 4. American Cancer Society
- 5. Queensland Institute of Medical Research
- 6. Université Lyon
- 7. Université McGill
- 8. University of Chicago
Description
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10−8, HR = 1.14, 95% CI: 1.09–1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10−8, HR = 1.27, 95% CI: 1.17–1.38) and 4q32.3 (rs4691139, P = 3.4×10−8, HR = 1.20, 95% CI: 1.17–1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10−4). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.
Files
journal.pgen.1003212.pdf
Files
(7.2 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:4b9c2dd1df8f72144fedb5d9961c46a6 |
3.0 MB | Preview Download |
|
Supporting information md5:c78f29f539fc072a7b2a08b51d3bbda6 |
4.2 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1371/journal.pgen.1003212
- Other
- oai:uchicago.tind.io:7972
Funding
- National Institutes of Health
- CA128978
- NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer
- CA116201
- U.S. Department of Defense Ovarian Cancer
- Idea award
- Breast Cancer Research Foundation
- Komen Foundation for the Cure
- Cancer Research UK
- C12292/A11174
- Cancer Research UK
- C1287/A10118
- European Commission
- Seventh Framework Programme
- National Cancer Institute
- CA-06-503
- Breast Cancer Family Registry
- Cancer Care Ontario
- U01 CA69467
- Cancer Prevention Institute of California
- U01 CA69417
- Columbia University
- U01 CA69398
- Fox Chase Cancer Center
- U01 CA69631
- Huntsman Cancer Institute
- U01 CA69446
- University of Melbourne
- U01 CA69638
- National Health and Medical Research Council of Australia
- New South Wales Cancer Council
- Victorian Health Promotion Foundation
- Victorian Breast Cancer Research Consortium
- National Institutes of Health
- P01 CA16094
- NHMRC
- National Institutes of Health
- R01 CA22435
- National Institutes of Health
- P30 CA13696
- National Institutes of Health
- P30 ES009089
- National Institutes of Health
- UL1 RR025764
- National Cancer Institute
- P30 CA042014
- Research Council of Lithuania
- LIG-19/2010
- Hereditary Cancer Association
- 10.0010.08
- LSC
- ESF
- Nr.2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016
- Cancer Association of South Africa
- Beckman Research Institute of the City of Hope
- Unknown funder
- Morris and Horowitz Families Endowed Professorship
- National Institutes of Health
- R01CA74415
- National Institutes of Health
- P30 CA033752
- NEYE Foundation
- Spanish Association against Cancer
- AECC08
- Spanish Association against Cancer
- RTICC 06/0020/1060
- Spanish Association against Cancer
- FISPI08/1120
- Mutua Madrileña Foundation
- Unknown funder
- SAF2010-20493
- National Cancer Institute
- RC4A153828
- Fondazione Italiana per la Ricerca sul Cancro
- Hereditary tumors
- Italian Association for Cancer Research
- IG 8713
- Italian Ministry of Health
- Extraordinary National Cancer Program 2006
- Italian Ministry of Education, University and Research
- Prin 2008
- Centro di Ascolto Donne Operate al Seno
- Italian citizens
- INT-Institutional strategic projects ‘5×1000’
- Dutch Cancer Society
- NKI1998-1854
- Dutch Cancer Society
- NKI2004-3088
- Dutch Cancer Society
- NKI2007-3756
- NWO
- 91109024
- Pink Ribbon
- 110005
- BBMRI
- CP46/NWO
- Cancer Research UK
- C1287/A11990
- Cancer Research UK
- C1287/A10118
- NIHR
- Cancer Research UK Grant
- C5047/A8385
- University of Kansas
- Cancer Center
- Kansas Bioscience Authority
- Eminent Scholar Program
- Unknown funder
- Chancellors Distinguished Chair in Biomedical Sciences Professorship
- Unknown funder
- R01CA140323
- German Cancer Aid
- 109076
- Center for Molecular Medicine Cologne
- Ligue National Contre le Cancer
- Association “Le cancer du sein, parlons-en!” Award
- Canadian Institutes of Health Research
- CIHR Team in Familial Risks of Breast Cancer
- National Cancer Institute
- CA 27469
- National Cancer Institute
- CA 37517
- National Cancer Institute
- CA 101165
- National Cancer Institute
- Intramural Research Program
- RETICC
- 06/0020/0021
- FIS
- research grant
- Instituto de Salud Carlos III
- Spanish Ministry of Economy and Competitivity
- European Regional Development Fund
- Helsinki University Central Hospital
- Research Fund
- Academy of Finland
- 132473
- Finnish Cancer Society
- Nordic Cancer Union
- Sigrid Juselius Foundation
- The Hong Kong Hereditary Breast Cancer Family Registry
- Dr. Ellen Li Charitable Foundation
- Hungarian Research Grant
- KTIA-OTKA CK-80745
- Norwegian EEA Financial Mechanism
- HU0115/NA/2008-3/ÖP-9
- Asociación Española Contra el Cáncer
- Spanish Health Research Foundation
- Ramón Areces Foundation
- Carlos III Health Institute
- Catalan Health Institute
- Autonomous Government of Catalonia
- ISCIIIRETIC
- RD06/0020/1051
- ISCIIIRETIC
- PI09/02483
- ISCIIIRETIC
- PI10/01422
- ISCIIIRETIC
- PI10/00748
- ISCIIIRETIC
- 2009SGR290
- ISCIIIRETIC
- 2009SGR283
- Polish Foundation of Science
- Warsaw Medical University
- fellowship
- Icelandic Association
- Walking for Breast Cancer Research
- Landspitali University Hospital
- Research Fund
- Canadian Institutes of Health Research
- CIHR Team in Familial Risks of Breast Cancer
- Canadian Breast Cancer Research Alliance
- 019511
- Ministry of Economic Development, Innovation and Export Trade
- PSR-SIIRI-701
- Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero della Salute
- Progetto Tumori Femminili
- Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero della Salute
- RFPS 2006-5-341353,ACC2/R6.9
- National Breast Cancer Foundation
- National Health and Medical Research Council
- Queensland Cancer Fund
- Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia
- Cancer Foundation of Western Australia
- NHMRC
- Senior Research Fellowship
- NHMRC
- National Breast Cancer Foundation and Cancer Australia
- 628333
- NIH
- CA128978
- NCI
- Specialized Program of Research Excellence (SPORE) in Breast Cancer
- U.S. Department of Defence
- Ovarian Cancer Idea award
- Breast Cancer Research Foundation
- Komen Foundation for the Cure
- Jewish General Hospital
- Weekend to End Breast Cancer
- Quebec Ministry of Economic Development, Innovation, and Export Trade
- Niehaus Clinical Cancer Genetics Initiative
- Andrew Sabin Family Foundation
- Lymphoma Foundation
- European Regional Development Fund
- State Budget of the Czech Republic
- National Institutes of Health
- 1R01 CA149429-01
- US National Cancer Institute
- Intramural Research Program
- Westat, Rockville, MD
- NO2-CP-11019-50
- Westat, Rockville, MD
- N02-CP-65504
- Clalit Health Services
- Israel Cancer Association
- Russian Foundation for Basic Research
- 11-04-00227
- Russian Foundation for Basic Research
- 12-04-00928
- Russian Foundation for Basic Research
- 12-04-01490
- Federal Agency for Science and Innovations
- 02.740.11.0780
- Royal Society
- International Joint grant
- Ohio State University Comprehensive Cancer Center
- Ministry of Science, Technology and Innovation
- Ministry of Higher Education
- Cancer Research Initiatives Foundation
- Israel Cancer Association
- Israeli Inherited Breast Cancer Consortium
- Swedish Cancer Society
- National Cancer Institute
- Ralph and Marion Falk Medical Research Trust
- Entertainment Industry Fund National Women's Cancer Research Alliance
- Jonsson Comprehensive Cancer Center Foundation
- UCSF Cancer Risk Program
- Helen Diller Family Comprehensive Cancer Center
- CRUK
- project grant
- National Institutes of Health
- R01-CA102776
- National Institutes of Health
- R01-CA083855
- Rooney Family Foundation
- Susan G. Komen Foundation for the Cure
- Macdonald Family Foundation
- Victorian Cancer Agency
- Cancer Australia
- National Breast Cancer Foundation
- American Cancer Society
- Early Detection Professorship